Leonard D'Amico
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti–PD-1/L1 antibody–based combinations. Augmenting checkpoint inhibitor–mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses. Patients and Methods: Patients with urothelial cancer after platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by the objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines. Results: CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities and lower grade 3 to 4 treatment-related adverse events compared with atezolizumab monotherapy. The ORR was 26.3% for the combination therapy versus 23.8% for atezolizumab alone (P = 0.428). The complete response rate was 10.5% for the combination therapy versus 4.8% for monotherapy. Three patients on combination therapy had responses >21 months versus one with monotherapy. CD4+ and CD8+ T-lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cells. Patients who responded to treatment exhibited elevated baseline levels of CCL4 and reduced levels of VEGFA and TNF. Conclusions: Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the complete response rate, and durable responses exceeding 2 years. However, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.
Year:
2025
Pharmacodynamics of CD4+ (A) and CD8+ (B) T cell populations in the experimental arm showing fold-change from baseline of % of T lymphocyte subsets. Significant differences were most observed in the CD4+ effector memory T cell population.
Year:
2025
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti–PD-1/L1 antibody–based combinations. Augmenting checkpoint inhibitor–mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses. Patients and Methods: Patients with urothelial cancer after platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by the objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines. Results: CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities and lower grade 3 to 4 treatment-related adverse events compared with atezolizumab monotherapy. The ORR was 26.3% for the combination therapy versus 23.8% for atezolizumab alone ( P = 0.428). The complete response rate was 10.5% for the combination therapy versus 4.8% for monotherapy. Three patients on combination therapy had responses >21 months versus one with monotherapy. CD4 + and CD8 + T-lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cells. Patients who responded to treatment exhibited elevated baseline levels of CCL4 and reduced levels of VEGFA and TNF. Conclusions: Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the complete response rate, and durable responses exceeding 2 years. However, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.
Year:
2025
Pharmacodynamics showing fold-change from baseline of % of T lymphocyte memory subsets for (A,C) CD4+ T cells and (B,D) CD8+ T cells. Tscm lymphocyte subset the most highly significantly expanded T cell subset for both CD4+ and CD8+ T cells and seen only in (A,B) experimental arm and not (C,D) control arm subjects. (E,F) CX3CR1 expression in CD4+ Tscm lymphocytes trended lower in responding patients. T lymphocytes were evaluated and analyzed by 14-color flow cytometry on cryopreserved PBMCs. TE = Terminal Effector, EM = Effector Memory, CM = Central Memory. N = Naïve, SCM = T memory Stem Cells.
Year:
2025
Collaborators (3)
Elad Sharon
Associate Professor
Harvard University
Evan Y. Yu
University of Washington
Russell K. Pachynski
Washington University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.